Dr. Reddy’s announces the launch of over-the-counter store brand equivalent of Prilosec OTC® (Omeprazole Delayed-Release) ...
December 11 2018 - 12:43AM
Business Wire
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, along with its subsidiaries together referred to as “Dr.
Reddy’s”) announced today the launch of Omeprazole Delayed-Release
Tablets, 20 mg, an over-the-counter (OTC) store-brand equivalent of
Prilosec® OTC (omeprazole delayed-release) Tablets, 20 mg, in the
United States market as approved by the U.S. Food and Drug
Administration (USFDA).
OTC Omeprazole Delayed-Release Tablets, 20 mg, is a proton pump
inhibitor used to treat frequent heartburn occurring two or more
days per week in adults*.
"This launch illustrates our continued commitment to the OTC
business as well as the depth and breadth of our OTC portfolio,”
says Milan Kalawadia, Vice President and Head, US OTC and
Speciality Rx businesses, Dr. Reddy’s Laboratories. “We look
forward to collaborating with our customers to provide
high-quality, affordable alternatives to consumers.”
The combined market of Prilosec OTC® and private label
omeprazole OTC products had U.S. retail sales of approximately $492
million for the most recent twelve months ending in October 2018
according to IRI†.
Dr. Reddy’s Omeprazole Delayed-Release Tablets, 20 mg, is
available in 14 count bottles sold in cartons of 1, 2, or 3 bottles
each. Each bottle contains one complete 14-day course of treatment.
Use only as directed.
*May take 1 to 4 days for full effect. †IRI Latest 52 wks.
period ending October 2018
Prilosec® is a registered trademark of AstraZeneca AB.
OTC-___-1218
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management’s current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates , interest rates , persistency
levels and frequency / severity of insured loss events (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues. The company assumes no
obligation to update any information contained herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181210005905/en/
DR. REDDY'S LABORATORIES LTD.INVESTOR
RELATIONSSAUNAK SAVLA, (Ph:
+91-40-49002135)saunaks@drreddys.comorMEDIA RELATIONSCALVIN
PRINTER, (Ph: +91-40- 49002121)calvinprinter@drreddys.com
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Sep 2023 to Sep 2024